All Outputs (83)

The risk of keratinocyte carcinoma (KC) in psoriasis patients receiving biologic therapy compared with conventional systemic therapy: Results from the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2018)
Presentation / Conference
Mason, K. J. (2018, August). The risk of keratinocyte carcinoma (KC) in psoriasis patients receiving biologic therapy compared with conventional systemic therapy: Results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Poster presented at 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague Congress Centre, Prague, Czech Republic

Background: Whether psoriasis patients exposed to biologic therapies have an elevated risk of KC (basal cell carcinoma [BCC] or cutaneous squamous cell carcinoma [cSCC]) remains uncertain. Objectives: To determine whether such patients were at hig... Read More about The risk of keratinocyte carcinoma (KC) in psoriasis patients receiving biologic therapy compared with conventional systemic therapy: Results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Real-world persistence and effectiveness of conventional systemic therapies in the treatment of psoriasis: A systematic review (2018)
Presentation / Conference
Williams, S., Mason, K. J., Yiu, Z., McElhone, K., Warren, R. B., & Griffiths, C. E. (2018, August). Real-world persistence and effectiveness of conventional systemic therapies in the treatment of psoriasis: A systematic review. Paper presented at 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague Congress Centre, Prague, Czech Republic

Background: The effectiveness and persistence of biologic therapies is better understood than more commonly prescribed conventional systemic therapies in clinical practice. Objectives: To evaluate large-scale observational studies investigating th... Read More about Real-world persistence and effectiveness of conventional systemic therapies in the treatment of psoriasis: A systematic review.

A real-world comparison of effectiveness and safety outcomes between clinical trial eligible and ineligible patients in the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2018)
Conference Proceeding
Mason, K. J. (2018). A real-world comparison of effectiveness and safety outcomes between clinical trial eligible and ineligible patients in the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Background: There is preliminary evidence that psoriasis patients eligible for clinical trials of biologics are not representative of real-world patients. Objectives: To determine whether patients enrolled in BADBIR identified as eligible or ineli... Read More about A real-world comparison of effectiveness and safety outcomes between clinical trial eligible and ineligible patients in the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland (2018)
Journal Article
Garcia-Doval, I., Descalzo, M., Mason, K., Cohen, A., Ormerod, A., Gómez-García, F., …Network, T. P. (2018). Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland. British Journal of Dermatology, 179(4), 863-871. https://doi.org/10.1111/bjd.16715

Background Cancer risk following long‐term exposure to systemic immunomodulatory therapies in patients with psoriasis is possible. Objectives To assess a dose–response relationship between cumulative length of exposure to biological therapy and... Read More about Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland.

Missing Information About Study Funding (2018)
Journal Article
Mason, K. J., Barker, J. N., Smith, C. H., Hampton, P. J., Lunt, M., McElhone, K., …Study Group, T. B. (2018). Missing Information About Study Funding. JAMA Dermatology, 154(7), 852. https://doi.org/10.1001/jamadermatol.2018.2319

In the Original Investigation titled “Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible And Ineligible Patients in BADBIR,”1 published online March 28, 2018, there was information omitted regarding study fu... Read More about Missing Information About Study Funding.

THE RISK OF KC IN PSORIASIS PATIENTS RECEIVING BIOLOGICS COMPARED TO CONVENTIONAL SYSTEMIC THERAPIES (2018)
Presentation / Conference
Mason, K. (2018, June). THE RISK OF KC IN PSORIASIS PATIENTS RECEIVING BIOLOGICS COMPARED TO CONVENTIONAL SYSTEMIC THERAPIES. Poster presented at 5th World Psoriasis & Psoriatic Arthritis Conference, Stockholm, Sweden

Introduction: Whether psoriasis patients exposed to biologic therapies have an elevated risk of keratinocyte carcinoma (KC), including basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC) remains uncertain. Objective:The aim of t... Read More about THE RISK OF KC IN PSORIASIS PATIENTS RECEIVING BIOLOGICS COMPARED TO CONVENTIONAL SYSTEMIC THERAPIES.

238 The risk of keratinocyte carcinoma (KC) in psoriasis patients receiving biologic therapy compared to conventional systemic therapy: Results from The British Association of Dermatologists Biologic Interventions Register (BADBIR) (2018)
Journal Article
Mason, K. (2018). 238 The risk of keratinocyte carcinoma (KC) in psoriasis patients receiving biologic therapy compared to conventional systemic therapy: Results from The British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 138(5), S41. https://doi.org/10.1016/j.jid.2018.03.244

Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. (2018)
Journal Article
Mason. (2018). Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatology, 154(5), 581 - 588. https://doi.org/10.1001/jamadermatol.2018.0183

Importance: Patients with psoriasis enrolled in clinical trials of biologics may not be representative of the real-world population. There is evidence that patients ineligible for such trials have a greater risk of serious adverse events (SAEs), but... Read More about Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR..

509 Association between biologics and major cardiovascular events in adult patients with plaque psoriasis: A cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2018)
Journal Article
Rungapiromnan, W., Mason, K., Lunt, M., McElhone, K., Rutter, M., Warren, R., …Ashcroft, D. (2018). 509 Association between biologics and major cardiovascular events in adult patients with plaque psoriasis: A cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 138(5), S87. https://doi.org/10.1016/j.jid.2018.03.517

The association between biologics and major cardiovascular events (CVEs) in adult patients with plaque psoriasis is unclear. We used prospective cohort data from BADBIR to compared CVE risk associated with different therapies in participants recruite... Read More about 509 Association between biologics and major cardiovascular events in adult patients with plaque psoriasis: A cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Psychosocial factors partially mediate the relationship between mechanical hyperalgesia and self-reported pain (2018)
Journal Article
Mason, K. J., O'Neill, T. W., Lunt, M., Jones, A. K. P., & McBeth, J. (2018). Psychosocial factors partially mediate the relationship between mechanical hyperalgesia and self-reported pain. Scandinavian Journal of Pain, 18(1), 59-69. https://doi.org/10.1515/sjpain-2017-0109

Background and aims: Amplification of sensory signalling within the nervous system along with psychosocial factors contributes to the variation and severity of knee pain. Quantitative sensory testing (QST) is a non-invasive test battery that assesse... Read More about Psychosocial factors partially mediate the relationship between mechanical hyperalgesia and self-reported pain.

Risk of cancer in patients with psoriasis on biological therapies: a systematic review (2018)
Journal Article
Peleva, E., Exton, L. S., Kelley, K., Kleyn, C. E., Mason, K. J., & Smith, C. H. (2018). Risk of cancer in patients with psoriasis on biological therapies: a systematic review. British Journal of Dermatology, 178(1), 103-113. https://doi.org/10.1111/bjd.15830

Background Biological therapies are highly effective in psoriasis, but have profound effects on innate and adaptive immune pathways that may negatively impact on cancer immunosurveillance mechanisms. Objectives To investigate the risk of cancer... Read More about Risk of cancer in patients with psoriasis on biological therapies: a systematic review.

Real-world use of fumaric acid esters in psoriasis: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2017)
Presentation / Conference
Mason, K. J., Lunt, M., Hunter, H. J., Jabbar-Lopez, Z. K., Kirby, B., Kleyn, C. E., …Grp, B. A. D. B. I. R. S. (2017, November). Real-world use of fumaric acid esters in psoriasis: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Paper presented at Psoriasis Gene to Clinic, 8th International Congress, The Queen Elizabeth II Conference Centre, London, UK

A real-world comparison of effectiveness and safety outcomes between clinical trial-eligible and -ineligible patients in the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2017)
Presentation / Conference
Mason, K., Barker, J., Smith, C., Hampton, P., Lunt, M., McElhone, K., …Burden, A. (2017, November). A real-world comparison of effectiveness and safety outcomes between clinical trial-eligible and -ineligible patients in the British Association of Dermatologists Biologic Interventions Register (BADBIR). Paper presented at Psoriasis Gene to Clinic, 8th International Congress, The Queen Elizabeth II Conference Centre, London, UK

Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength (2017)
Journal Article
Thorneloe, R. J., Griffiths, C. E., Emsley, R., Ashcroft, D. M., Cordingley, L., Biologic Interventions Register, B. A. O. D., …Warren, R. (2018). Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength. Journal of Investigative Dermatology, 138(4), 785 - 794. https://doi.org/10.1016/j.jid.2017.11.015

Medication non-adherence is a missed opportunity for therapeutic benefit. We assessed "real-world" levels of self-reported non-adherence to conventional and biologic systemic therapies used for psoriasis and evaluated psychological and biomedical fac... Read More about Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength.

Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). (2017)
Journal Article
Iskandar, I. Y., Warren, R. B., Lunt, M., Mason, K. J., Evans, I., McElhone, K., …Griffiths, C. E. (2018). Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 138(4), 775 - 784. https://doi.org/10.1016/j.jid.2017.09.044

Little is known about the drug survival of second-line biologic therapies for psoriasis in routine clinical practice. We assessed drug survival of second-line biologic therapies and estimated the risk of recurrent discontinuation due to adverse event... Read More about Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)..

Completeness of reporting of overnight hospitalisations to a psoriasis pharmacovigilance register and the National Health Service Wales Informatics Service (2017)
Presentation / Conference
Mason, K. J., Ali, H., Reynolds, N. J., Burden, A. D., Smith, C. H., Evans, I., …Griffiths, C. E. . M. (2017, August). Completeness of reporting of overnight hospitalisations to a psoriasis pharmacovigilance register and the National Health Service Wales Informatics Service. Paper presented at 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Palais de Congres de Montreal, Montreal, Canada

Background: The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a longitudinal, observational, web-based pharmacovigilance register of patients with moderate-to-severe psoriasis. Patients are currently recruited from... Read More about Completeness of reporting of overnight hospitalisations to a psoriasis pharmacovigilance register and the National Health Service Wales Informatics Service.

Persistence with second-line biological therapies in patients with psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2017)
Presentation / Conference
Iskandar, I. Y. K., Warren, R., Lunt, M., Mason, K. J., Evans, I., McElhone, K., …Ashcroft, D. M. (2017, July). Persistence with second-line biological therapies in patients with psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Paper presented at The 97th Annual meeting of the British Association of Dermatologists, The Arena and Convention Centre Liverpool, Liverpool, United Kingdom

Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study (2017)
Journal Article
Davison, N. J., Warren, R. B., Mason, K. J., McElhone, K., Kirby, B., Burden, A. D., …Griffiths, C. E. M. (2017). Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study. British Journal of Dermatology, 177(3), 828-836. https://doi.org/10.1111/bjd.15551

PATTERNS OF INDEX BIOLOGIC DRUG REGISTRATIONS TO A PHARMACOVIGILANCE REGISTER OF PSORIASIS PATIENTS (2016)
Journal Article
Mason, K. J., Evans, I., McElhone, K., Lunt, M., Hussain, S., Kirby, B., …Griffiths, C. E. (2016). PATTERNS OF INDEX BIOLOGIC DRUG REGISTRATIONS TO A PHARMACOVIGILANCE REGISTER OF PSORIASIS PATIENTS. Value in Health, 19(7), A573-A573

Completeness of Reporting of Basal Cell Carcinoma and Squamous Cell Carcinoma to a Pharmacovigilance Register and the Health and Social Care Information Centre (2016)
Presentation / Conference
Mason, K. J., Lunt, M., Reynolds, N. J., Ashcroft, D. M., Burden, A. . D., Ormerod, A. D., …Griffiths, C. E. . M. (2016, August). Completeness of Reporting of Basal Cell Carcinoma and Squamous Cell Carcinoma to a Pharmacovigilance Register and the Health and Social Care Information Centre. Paper presented at The Convention Centre Dublin, Dublin, Ireland

32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management